Dr. Sengupta is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
University of North Carolina, Chapel Hill
Chapel Hill, NC 27599- Is this information wrong?
Summary
- Dr. Soma Sengupta is a neuro-oncologist and clinical trialist at the University of North Carolina, Chapel Hill. She received her medical degree from University of Cambridge School of Medicine and has been in practice 20 years. She also speaks multiple languages, including French and Bengali. She specializes in neurooncology and is experienced in neuro-oncology and brain tumor survivorship.
Education & Training
Beth Israel Deaconess Medical Center/Harvard Medical SchoolResidency, Neurology, 2008 - 2011
Johns Hopkins UniversityResidency, Internal Medicine, 2007 - 2008
University of Cambridge School of MedicineClass of 2000
Certifications & Licensure
OH State Medical License 2019 - 2026
NC State Medical License 2023 - 2024
KY State Medical License 2021 - 2024
GA State Medical License 2016 - 2019
MA State Medical License 2011 - 2016- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- Leonard Tow Humanism Award Gold Humanism Honor Society, 2023
- Joslin Haggart Yeiser Unsung Hero Award Cancer Family Care, 2022
Clinical Trials
- Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma Start of enrollment: 2018 May 20
- MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas Start of enrollment: 2019 Sep 29
- Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM Start of enrollment: 2020 Dec 08
Publications & Presentations
PubMed
- A Review of Approaches to Potentiate the Activity of Temozolomide against Glioblastoma to Overcome Resistance.Aniruddha S Karve, Janki M Desai, Sidharth N Gadgil, Nimita Dave, Gary A Gudelsky, Timothy N Phoenix, Biplab DasGupta, David R Plas, Pankaj B Desai, Trisha M Wise-Drap...> ;International Journal of Molecular Sciences. 2024 Mar 12
- Chaetocin-mediated SUV39H1 inhibition targets stemness and oncogenic networks of diffuse midline gliomas and synergizes with ONC201.Dazhuan Eric Xin, Yunfei Liao, Rohit Rao, Sean Ogurek, Soma Sengupta, Mei Xin, Arman Esshaghi Bayat, William L Seibel, Richard T Graham, Q Richard Lu, Carl Koschmann> ;Neuro-Oncology. 2024 Apr 5
- Factors associated with radiation necrosis and intracranial control in patients treated with immune checkpoint inhibitors and stereotactic radiotherapy.Jacob Hall, Kevin Lui, Xianming Tan, John Shumway, Frances Collichio, Stergios Moschos, Soma Sengupta, Rekha Chaudhary, Carolyn Quinsey, Sivakumar Jaikumar, Jonathan F...> ;Radiotherapy and Oncology. 2023 Dec 1
- Join now to see all
Journal Articles
- Chapter 50 - Brain Cancer Genomics and EpigenomicsSoma Sengupta, Scott L Pomeroy, ScienceDirect
Authored Content
- Humanizing Brain TumorsJuly 2022
Press Mentions
Study Reveals Potential New Treatment for Patients with Metastatic MelanomaFebruary 26th, 2020
UC researchers study ‘liquid biopsy’December 8th, 2020
Researchers review neuroimaging for patients and show altered mental state and stroke dominateDecember 8th, 2020- Join now to see all
Professional Memberships
- Society of Neuro-oncologyMember
- Member
- ASCOMember
- AACRMember
- Royal College of Medicine, LondonFellow
- Royal Society of MedicineMember
Other Languages
- French, Bengali
External Links
- LinkedInhttps://www.linkedin.com/in/soma-sengupta-25b52011/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
